Taro Pharmaceutical (NYSE:TARO): Q1 EPS of -$11.37 may not be comparable to consensus of $1.16.
Revenue of $117.63M (-27.1% Y/Y) misses by $40.72M.
Wednesday, July 29, 2020
FDA OKs pooled sample testing for COVID-19 at Quest
The FDA has signed off on pooled sample testing at Quest Diagnostics (NYSE:DGX) for the detection of SARS-CoV-2. The new method will allow the reference lab to boost daily testing capacity to ~170K from 135K in the next few weeks with an upside of 185K tests by Labor Day.
Related ticker: LabCorp (NYSE:LH)
Krystal Biotech launches late-stage study on gene therapy in skin disorder
Krystal Biotech (KRYS -3.2%) initiates a pivotal Phase 3 (GEM-3) trial evaluating topical gene therapy bercolagene telserpavec (B-VEC) (previously KB103) for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters easily.
The trial will evaluate the efficacy and safety of either B-VEC or placebo in ~30 in patients suffering from both recessive and dominant forms of DEB.
The primary endpoint is complete wound healing at weeks 20, 22 and 24 versus placebo.
The company expects to report topline data and file a U.S. marketing application in 2021.
The company also expects that its second GMP facility, ASTRA, will be operational in 1H of 2022.
Amedisys up on Q2 reports beat
Amedisys (AMED +6.3%) reported Q2 revenue of $485M (-1.6% Y/Y)
Home health segment: medicare revenue equaled $192.2M, while non-medicare revenue of $97.3M
Hospice segment: medicare revenue equaled $167M, while non-medicare revenue of $10.1M
Personal Care segment: non-medicare revenue of $17.7M
Adjusted EBITDA of $66.4M vs. $61.4M last year.
Adjusted EPS of $1.34 vs. $1.21 last year
Gross margin of 121.3M.
2020 Guidance: Revenue $2.04B-2.07B, Adjusted EBITDA $245M-255M, Adjusted EPS $4.84-5.06.
Hologic EPS beats by $0.37, beats on revenue
Revenue of $822.9M (-3.5% Y/Y) beats by $199.94M.
Adj. gross margin of 64.7% beats consensus of 57.5% and Adj. operating margin of 33% beats consensus of 25.8%.
Merit Medical Systems EPS beats by $0.24, beats on revenue
Merit Medical Systems (NASDAQ:MMSI): Q2 Non-GAAP EPS of $0.31 beats by $0.24; GAAP EPS of -$0.34 misses by $0.15.
Revenue of $218.37M (-14.5% Y/Y) beats by $25.7M.
Subscribe to:
Posts (Atom)